Home   »   Media

Media

  • PLOS Genetics
  • This article in PLOS Genetics shows that telomerase activation using AAV9 vectors and telomerase gene is not necessarily associated with increased cancer risk and supports the safety of AAV-mediated telomerase activation as an innovative treatment for age-related disease.

  • EMBO
  • Published in the pre-eminent scientific journal EMBO, this article demonstrated the efficacy of telomerase therapy in treating aging in animals, without any evidence of side effects.

  • JAMA
  • Published in the Journal of the American Medical Association (JAMA), this was the first medical article to discuss the potential use of telomerase therapy in treating human disease.

  • Nature
  • This article in Nature showed that telomerase activation could not only increase health and longevity, but resulted in regrowth of lost CNS volume, suggesting the potential for human CNS disease.

  • Phacilitate Investment Report
  • This industry report, citing Telocyte, notes that “there is little doubt of the role gene therapies will play in the future of medicine… The advanced therapy sector is a rapidly growing industry which offers substantial opportunities for return on investment (ROI)."

  • IdeaCity
  • In 2014, Dr. Fossel gave this short (17-minute) talk at IdeaCity, giving a clear and concise presentation of the rationale for and the history of telomerase therapy, as well as the plans for human trials.

  • Newsletter Q4 2018
  • The field of Alzheimer’s research remains frustratingly unchanged, characterized by frequent claims of research breakthroughs, followed by predictable clinical failures.

  • Newsletter Q3 2018
  • The major problem with innovation is that it is innovative. Incremental approaches to Alzheimer’s intervention have...

  • Newsletter Q2 2018
  • Alzheimer's disease has been with human beings as long as we've been human. Few of us grew old enough to suffer from...

  • Newsletter Q1 2018
  • Gene therapy has made remarkable progress since the death of Jesse Gelsinger, twenty years ago. Since then, gene therapy has gradually climbed back toward clinical success...
  • Newsletter Q4 2017
  • Many biotech firms, particularly those aimed at Alzheimer's disease, find that their major problem is finding the "signal in the noise"...

  • Newsletter Q3 2017
  • In the following article the current progress, Telocyte patient registry and the perspective of Alzheimer’s is being discussed.

  • Newsletter Q2 2017
  • This article is about the investment funding, the FDA discussion and animal study as well as the participants in Telocyte.

  • Newsletter Q1 2017
  • The following newsletter describes the tasks at Telocyte, the cause of Alzheimer’s and includes a comment from Peter Rayson, Founder and CEO of Telocyte.

  • Newsletter Q4 2016
  • This article is about how to prevent and cure Alzheimer’s disease by resetting glial cell function and reversing the damage in neurons and the cognitive decline.